Abstract
Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have